National Academy of Sciences | 150 Year Anniversary

Questions? Call 800-624-6242

| Items in cart [0]

The National Academies Press

PAPERBACK
price:$63.25
add to cart

Rights & Permissions

topleft topright

Economic Models of Colorectal Cancer Screening in Average-Risk Adults: Workshop Summary (2005)
Board on Science, Technology, and Economic Policy (STEP)
National Cancer Policy Board (NCPB)

Citation Manager

. "Appendix D Overview of Harvard Model--Karen M. Kuntz, ScD.." Economic Models of Colorectal Cancer Screening in Average-Risk Adults: Workshop Summary. Washington, DC: The National Academies Press, 2005.

Please select a format:

BibTeX EndNote RefMan


Page
60
bottomleft bottomright

The following HTML text is provided to enhance online readability. Many aspects of typography translate only awkwardly to HTML. Please use the page image as the authoritative form to ensure accuracy.


Economic Models of Colorectal Cancer Screening in Average-Risk Adults: Workshop Summary

REFERENCES

Frazier AL, Colditz GA, Fuchs CS, Kuntz KM. 2000. Cost-effectiveness of screening for colorectal cancer in the general population. JAMA. 284(15):1954–1961.


Mandel JS, Church TR, Bond JH, Ederer F, Geisser MS, Mongin SJ, Snover DC, Schuman LM. 2000. The effect of fecal occult-blood screening on the incidence of colorectal cancer. N Engl J Med. 343(22):1603–1607.

Mandel JS, Church TR, Ederer F, Bond JH. 1999. Colorectal cancer mortality: Effectiveness of biennial screening for fecal occult blood. J Natl Cancer Inst. 91(5):434–437.


Taplin SH, Barlow W, Urban N. 1995a. Erratum: Stage, age, comorbidity, and direct costs of colon, prostate, and breast cancer care. J Natl Cancer Inst. 87(8):610.

Taplin SH, Barlow W, Urban N, Mandelson MT, Timlin DJ, Ichikawa L, Nefcy P. 1995b. Stage, age, comorbidity, and direct costs of colon, prostate, and breast cancer care. J Natl Cancer Inst. 87(6):417–426.

Page
60
Front Matter (R1-R8)
Workshop Summary (1-30)
References (31-34)
Appendix A Workshop Agenda: Economic Models of Colorectal Cancer Screening in Average-Risk Adults (35-36)
Appendix B Workshop Participants (37-38)
Appendix C Workshop Speaker and Staff Biographies (39-44)
Appendix D Overview of Harvard Model--Karen M. Kuntz, ScD. (45-60)
Appendix E Description of the Laudabaum Colorectal Cancer Screening Model--Uri Ladabaum, M.D., M.S. (61-72)
Appendix F MISCAN-colon: An Overview--Marjolein van Ballegooijen, Iris Vogelaar, Rob Boer, Franka Loeve, Ann Zauber, Gerrit van Oortmar, and Dik Habbema (73-83)
Appendix G The Vanderbilt Colorectal Cancer Model--R.M. Ness, R.W. Klein, R.S. Dittus (84-104)
Appendix H Overview of the Vijan Colorectal Cancer Screening Model--Sandeep Vijan, M.D., M.S. (105-117)
Appendix I Cost-Effectiveness Analyses of Colorectal Cancer Screening: Results from a Pre-conference Modeling Exercise--Michael Pignone, M.D., (118-153)
Appendix J Recent Findings on Test Performance--Brian P. Mulhall, M.D., M.P.H. (154-188)
Appendix K Cost Issues in Cost Effectiveness Modeling of Colorectal Cancer Screening--Martin L. Brown, Ph.D. (189-207)
Appendix L Current Evidence on Compliance --Sally W. Vernon, M.A., Ph.D. (208-219)
Appendix M Recent Trends in Follow-up Surveillance in Medicare Beneficiaries--Todd Anderson, M.S. (220-231)
Appendix N Preliminary Results from CDC (232-240)
Appendix O Colorectal Cancer Surveillance Testing After Polypectomy--Deborah Schrag, M.D., M.P.H. (241-262)
Appendix P Natural History of Colorectal Adenomas and Cancer--T. R. Levin, M.D. (263-284)
Appendix Q CISNET—Cancer Intervention and Surveillance--Eric J. (Rocky) Feuer, Ph.D. (285-300)